Matthew Martinson

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin, Vickie Bowcut, Andrew Calinisan et al. · Nature Medicine · 2022 · 507 citations

Medicine, Medicinal Chemistry, Oncology +9

Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors

James F. Blake, Rui Xu, Josef R. Bencsik et al. · Journal of Medicinal Chemistry · 2012 · 188 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Discovery of (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development

James F. Blake, Michael Burkard, Jocelyn Chan et al. · Journal of Medicinal Chemistry · 2016 · 158 citations · Full text

Medicine, Oncology, Pharmacology +17

Potent and selective pyrazole-based inhibitors of B-Raf kinase

Joshua D. Hansen, Jonas Grina, Brad Newhouse et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 65 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

A potential therapeutic target for FLT3-ITD AML: PIM1 kinase

Amir T. Fathi, Omotayo Arowojolu, Ian Swinnen et al. · Leukemia Research · 2011 · 56 citations · Full text

Medicine, Molecular Biology, Oncology +12